Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
Wenjing Xu, Chunping Ye, Qing Xin, et al.
Materials Today Bio (2022) Vol. 16, pp. 100358-100358
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Syed Faheem Askari Rizvi, Lin‐Jie Zhang, Haixia Zhang, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 2, pp. 309-334
Open Access | Times Cited: 11
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1398-1398
Open Access | Times Cited: 7
Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
Syed Faheem Askari Rizvi, Haixia Zhang, Quan Fang
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2420-2471
Closed Access | Times Cited: 6
A green bioanalytical spectrofluorimetric approach for estimation of Avapritinib anti-tumor drug; application to quality control and clinical studies
Baher I. Salman, Roshdy E. Saraya, Yasser F. Hassan, et al.
Bioanalysis (2025) Vol. 17, Iss. 1, pp. 31-40
Closed Access
Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
Harpinder K. Brar, Jiney Jose, Zimei Wu, et al.
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 59-59
Open Access | Times Cited: 27
Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma
Wenjing Xu, Meng Yang, Wenning Zhang, et al.
Materials Today Bio (2023) Vol. 24, pp. 100902-100902
Open Access | Times Cited: 8
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted Therapy
Francesca Musumeci, Silvia Schenone
Pharmaceutics (2024) Vol. 16, Iss. 5, pp. 625-625
Open Access | Times Cited: 2
A novel GSH-activable theranostic probe containing kinase inhibitor for synergistic treatment and selective imaging of tumor cells
Caiyun Liu, Yan Zhang, Weimin Sun, et al.
Talanta (2023) Vol. 260, pp. 124567-124567
Closed Access | Times Cited: 7
Gold-iron oxide (Au/Fe3O4) magnetic nanoparticles as the nanoplatform for binding of bioactive molecules through self-assembly
Elizabeth C. H. T. Lau, Michelle Åhlén, Ocean Cheung, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 6
Tumor-targeting polymer nanohybrids with amplified ROS generation for combined photodynamic and chemodynamic therapy
Xiaodan Chen, Danling Cheng, Ningyue Yu, et al.
Journal of Materials Chemistry B (2023) Vol. 12, Iss. 5, pp. 1296-1306
Closed Access | Times Cited: 6
Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer
Nidhi Singh, Kolimi Prashanth Reddy, Priyanka Das, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 82, pp. 104315-104315
Closed Access | Times Cited: 5
QbD-driven RP-HPLC method for novel chemo-herbal combination, in-silico, force degradation studies, and characterization of dual drug-loaded polymeric and lipidic nanocarriers
Ankaj Kumar, Sandeep Jat, Pramod Kumar, et al.
Future Journal of Pharmaceutical Sciences (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Folate receptor-mediated delivery system based on chitosan coated polymeric nanoparticles for combination therapy of breast cancer
Sajjad Jamali, Behzad Jamali, Fatemeh Abedi, et al.
Journal of Biomaterials Science Polymer Edition (2024) Vol. 35, Iss. 5, pp. 605-627
Closed Access | Times Cited: 1
Recent trends and advances in nanosystems with tyrosine kinase inhibitors for image-guided cancer treatments
Ali Tarighatnia, Behrouz Foroughi‐Nia, Nader D. Nader, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 88, pp. 104938-104938
Closed Access | Times Cited: 4
Nanomaterials based on phase change materials for antibacterial application
Wenjing Xu, Linfeng Xu, Weilu Jia, et al.
Biomaterials Science (2022) Vol. 10, Iss. 22, pp. 6388-6398
Closed Access | Times Cited: 8
Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma
Hye Won Lee, Hee Seung Seo, Seon-Yong Yeom, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12634-12634
Open Access | Times Cited: 8
A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
Binhao Shi, Junli Chang, Xingyuan Sun, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Assessment of serum and synovial fluid MMP-3 and MPO as biomarkers for psoriatic arthritis and their relation to disease activity indices
Mariela Geneva‐Popova, Stanislava Popova‐Belova, Velichka Popova, et al.
Rheumatology International (2022) Vol. 42, Iss. 9, pp. 1605-1615
Closed Access | Times Cited: 6
Theranostics-enabling high-tech centers: the value of centralizing resources in countries in development
Pascal Kahlem, Pau Berenguer-Molins, Hakan Akbulut
F1000Research (2024) Vol. 13, pp. 283-283
Open Access
Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment
Sumit Roy, Vancha Harish, Sharfuddin Mohd, et al.
Advanced Therapeutics (2024)
Closed Access
Advancements in Nanocarrier-Mediated Sunitinib Delivery: Addressing Obstacles and Revealing its Therapeutic Promise in Oncological Treatment
Mohammad Javad Javid‐Naderi, Zohreh Abbasi, Sonia Fathi‐karkan, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 100, pp. 106107-106107
Closed Access
A nanotechnology driven effectual localized lung cancer targeting approaches using tyrosine kinases inhibitors: Recent progress, preclinical assessment, challenges, and future perspectives
Ankaj Kumar, Klaudi K. Vaiphei, Arvind Gulbake
International Journal of Pharmaceutics (2024), pp. 124745-124745
Closed Access
Nanotechnology for Nasopharyngeal Cancer Therapy and Improving Drug Stability and Biodistribution
Minmin Shao, Madineh Moradialvand, Francesca Della Sala, et al.
Advanced Materials Technologies (2024)
Closed Access
Ammonium Sulfate Gradient-Prepared Anlotinib-Loaded Liposomes for Potent Tumor Therapy with Decreased Side Effect
Ge Sun, Yubiao Huang, Xiaoyu Cheng, et al.
ACS Applied Nano Materials (2024)
Closed Access
Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma
Wenjing Xu, Meng Yang, Xuanlong Du, et al.
Micromachines (2023) Vol. 14, Iss. 3, pp. 613-613
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top